Branching Out Volume 28 Number 1 | Page 4

power of partnerships BVMC – the Partners who found the connection The Brain Vascular Malformation Consortium is an NIH funded program formed in 2003 with the goal of bringing together several organizations concerned with vascular malformations of the brain for common projects and to foster research that would benefit the field of neuroscience at large. The initial participants were the Sturge-Weber Foundation, the Angioma Alliance and the HHT, interested investigators, national centers and the Kennedy Kreiger Center at Johns Hopkins Medical Center. The SWF fostered this collaboration with the two other foundations and their researchers to apply for a Rare Disease Clinical Research Networking (RDCRN) Consortium Grant.   The Brain Vascular Malformation Consortium (BVMC) application was awarded the grant and joined a stellar group of not-for-profits utilizing a total of $117 million for research into their respective diseases. The BVMC funding goes directly to the researchers and their institutions with a nominal stipend to the SWF. The role of the SWF has been to support the BVMC in all aspects, especially channeling families and individuals with SWS into the BVMC research projects. The BVMC began Aim One of the current research program by enrolling appropriate families at participating hospitals and currently has 191 enrollees. Within the SWF sphere, any individual or family can participate by calling the SWF office to ask to be referred to one of these hospitals: • Detroit Children’s Hospital in Michigan • Nationwide Children’s Hospital in Columbus, Ohio • Kennedy Krieger Center at Johns Hopkins Medical Center in Baltimore • Will’s Eye Institute at Thomas Jefferson Medical Center, Philadelphia • Texas Children’s Hospital 4 The only qualifying questions are: Do you or your child have a diagnosis of SWS? Can you provide documentation? Your contact information is then sent to the hospital you choose and they contact you. That hospital then proceeds with the next step in the study. Aim 2 has completed enrollment of SWS samples and is no longer enrolling SWS subjects.  WHY IS THIS IMPORTANT? This will be the first large scale 5 year study and banking of Sturge-Weber syndrome tissue with participants recruited at 5 of the 10 SWF Centers of Excellence and the Kennedy Krieger Institute SWS Center. The goals of the study are to establish a scalable, GNAQ gene mutation relational database to facilitate observational studies and clinical trials; to use urine samples to identify angiogenic mediators as markers for disease progression and to use tissue and DNA samples for DNA analysis.                                                                                                         HOW DOES THIS RESEARCH BENEFIT ME? The identification of markers for progression would improve patient surveillance and optimize management of the syndrome and prepare for the day when treatment trials will be developed. It is our sincere belief this study will also further drive research into emerging related clinical and scientific investigations and clinical trials. Ultimately, improving your quality of life which is one of the reasons the SWF was founded in 1987. Without the work of the Consortium, which is on-going, the GNAQ gene mutation discovery would have been decades away. Celebrating 26 Years of Compassionate and Professional Service